189 related articles for article (PubMed ID: 34819663)
1. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H; Matsumoto S; Liu J; Tanaka K; Mori S; Hayashi K; Kumagai S; Shibata Y; Hayashida T; Watanabe K; Fukuhara T; Ikeda T; Yoh K; Kato T; Nishino K; Nakamura A; Nakachi I; Kuyama S; Furuya N; Sakakibara-Konishi J; Okamoto I; Taima K; Ebi N; Daga H; Yamasaki A; Kodani M; Udagawa H; Kirita K; Zenke Y; Nosaki K; Sugiyama E; Sakai T; Nakai T; Ishii G; Niho S; Ohtsu A; Kobayashi SS; Goto K
Nature; 2021 Dec; 600(7888):319-323. PubMed ID: 34819663
[TBL] [Abstract][Full Text] [Related]
2. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
3. The
Ibrahim R; Chahine C; Felefly T; Khalife N; Saleh K
Future Oncol; 2023 Feb; 19(4):273-275. PubMed ID: 36942735
[No Abstract] [Full Text] [Related]
4. LTK fusions: A new target emerges in non-small cell lung cancer.
Cooper AJ; Sequist LV; Johnson TW; Lin JJ
Cancer Cell; 2022 Jan; 40(1):23-25. PubMed ID: 35016028
[TBL] [Abstract][Full Text] [Related]
5. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
Yuan Y; Wang Z; Nie X; Zhang P; Li L
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):696-700. PubMed ID: 36172736
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
7. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
8. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
[TBL] [Abstract][Full Text] [Related]
9. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
10. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
[TBL] [Abstract][Full Text] [Related]
12. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
13. A Rare Fusion of CLIP1 and ALK in a Case of Non-Small-Cell Lung Cancer With Neuroendocrine Features.
Pinsolle J; Mondet J; Duruisseaux M; d'Alnoncourt S; Magnat N; de Fraipont F; Moro-Sibilot D; Toffart AC; Brambilla E; McLeer-Florin A
Clin Lung Cancer; 2019 Sep; 20(5):e535-e540. PubMed ID: 31171381
[No Abstract] [Full Text] [Related]
14. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
15. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.
Saigí M; Carcereny E; Morán T; Cucurull M; Domènech M; Hernandez A; Martinez-Cardús A; Pros E; Sanchez-Cespedes M
Cancer Treat Rev; 2022 Sep; 109():102430. PubMed ID: 35777135
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
Meng Z; Li T; Wang P; Lizaso A; Huang D
Cancer Biol Ther; 2021 Jan; 22(1):1-4. PubMed ID: 33380260
[TBL] [Abstract][Full Text] [Related]
18. Mouse model for ROS1-rearranged lung cancer.
Arai Y; Totoki Y; Takahashi H; Nakamura H; Hama N; Kohno T; Tsuta K; Yoshida A; Asamura H; Mutoh M; Hosoda F; Tsuda H; Shibata T
PLoS One; 2013; 8(2):e56010. PubMed ID: 23418494
[TBL] [Abstract][Full Text] [Related]
19. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
[TBL] [Abstract][Full Text] [Related]
20. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
